Pulmonx

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Analog Devices, Philips And 3 Stocks To Watch Heading Into Wednesday

News

Short Ideas

Markets

Trading Ideas

LUNG

SWTX

Top 3 Health Care Stocks You May Want To Dump In February

Stock Movers

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

Earnings

Penny Stocks

Health Care

Small Cap

Analyst Ratings

General

ENOV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witnessed exponential growth during the pandemic era. Even in the post-pandemic period, remote healthcare, a paperless environment and distant treatment paved the way for digital services.

5 Medical Info Systems Stock to Buy for a Stable Portfolio

Pulmonx Corp

Press Releases

Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024

Pulmonx Reports Third Quarter 2024 Financial Results

Pulmonx to Present at the Stifel 2024 Healthcare Conference

Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers

Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference

Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day

Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

EDAP Appoints Glen French to Board of Directors

EDAP

AngioDynamics

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

BrainsWay Ltd. - American Depositary Shares

BrainsWay

ClearPoint Neuro

CVRx

Delcath Systems

Alpha Tau Medical

Electromed

Inogen

LENSAR

Myomo

NeuroPace

Nevro

Orthofix Medical

Senseonics Holdings

Semler Scientific

Surmodics

Neuronetics

Stereotaxis

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Tech

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

Varex Imaging

ZimVie

Zynex

Wells Fargo

Citigroup

Stifel

Piper Sandler

Canaccord Genuity

Comments

Pulmonx

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga